“A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients with High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), pp. 482–496. doi:10.25251/skin.6.6.5.